SOURCE: Dynavax Technologies

Dynavax Technologies

July 06, 2010 16:00 ET

Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine

BERKELEY, CA--(Marketwire - July 6, 2010) -  Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approved HPV vaccines that target approximately 70 percent of HPV strains, Dynavax's goal is to develop a vaccine that provides immunity to nearly all cancer-causing strains of HPV. Each year, 470,000 cervical cancers are diagnosed worldwide, and 250,000 deaths are due to cervical cancers.

About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit

Contact Information

  • Contact:
    Michael Ostrach
    Vice President and Chief Business Officer
    Email Contact